1. Home
  2. REX vs MPLT Comparison

REX vs MPLT Comparison

Compare REX & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REX American Resources Corporation

REX

REX American Resources Corporation

HOLD

Current Price

$44.47

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$36.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REX
MPLT
Founded
1980
2018
Country
United States
United States
Employees
N/A
133
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
REX
MPLT
Price
$44.47
$36.90
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
170.0K
563.2K
Earning Date
05-27-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.56
N/A
Revenue
$650,487,000.00
N/A
Revenue This Year
$19.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$80.95
N/A
Revenue Growth
1.24
N/A
52 Week Low
$30.02
$12.24
52 Week High
$64.95
$40.43

Technical Indicators

Market Signals
Indicator
REX
MPLT
Relative Strength Index (RSI) 42.54 54.74
Support Level $41.97 $26.20
Resistance Level $48.91 $40.43
Average True Range (ATR) 1.38 2.75
MACD -0.14 -0.46
Stochastic Oscillator 4.02 35.78

Price Performance

Historical Comparison
REX
MPLT

About REX REX American Resources Corporation

REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: